NCT02978300View on ClinicalTrials.gov

HFNC Alone or Associated With NIV for Immunocompromised Patients Admitted to ICU for Acute Respiratory Failure

NACompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

January 21, 2017

Primary Completion Date

April 2, 2019

Study Completion Date

August 30, 2019

Conditions
Acute Respiratory FailureImmunosuppression
Interventions
DEVICE

NIV/HFNC

Pressure support level to achieve an expired tidal volume between 6 and 8 ml/kg of predicted body weight Positive end expiratory pressure from 5 to 10 cm H2O, aiming a PEEP level ≥ 8 cm H2O FiO2 set to achieve SpO2 ≥ 92%

DEVICE

HFNC

Gas flow of 60 l/min and FiO2 set to achieve SpO2 ≥ 92%

Trial Locations (1)

86000

CHU de Poitiers, Poitiers

All Listed Sponsors
lead

Poitiers University Hospital

OTHER

NCT02978300 - HFNC Alone or Associated With NIV for Immunocompromised Patients Admitted to ICU for Acute Respiratory Failure | Biotech Hunter | Biotech Hunter